Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03869476
Other study ID # 49RC18_0153_1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 30, 2019
Est. completion date January 30, 2024

Study information

Verified date September 2023
Source University Hospital, Angers
Contact Damien Luque Paz, Pharm.D.
Phone 0241355590
Email damien.luquepaz@chu-angers.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.


Description:

The diagnostic criteria for myeloproliferative neoplasia have recently been revised in the WHO 2016 classification, which now recognizes a new entity between essential thrombocythemia (TE) and overt myelofibrosis (or primary myelofibrosis): prefibrotic myelofibrosis. Prefibrotic myelofibrosis patients seem to have a poorer prognosis compared to essential thrombocythemia in term of overall survival and myelofibrotic evolution. The dichotomy between these diseases is based on the bone marrow biopsy evaluation and is challenging with a lack of reproducibility showed in the literature. This study aims to develop a diagnostic non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis. The parameters studied are : - spleen fibrosis by elastography - plasma cytokines levels - mutationnal landscape by NGS - CD34 circulating cells Bone marrow biopsy were reviewed by 2 anatomopathologists. Number of patients to be enrolled : 130


Recruitment information / eligibility

Status Recruiting
Enrollment 130
Est. completion date January 30, 2024
Est. primary completion date January 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Adult (18 years of age or older) with the diagnosis of essential thrombocytosis, prefibrotic myelofibrosis or overt myelofibrosis according to WHO 2016 criteria; - Patient who has not received specific treatment for neoplasms; - Patient who has signed the consent to participate in the study; - Patient who has consented to be included in the "Malignant Haemopathies" collection at the University Hospital of Angers or Brest and for whom the samples necessary for the study are available in the biocollection. Exclusion Criteria: - Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis; - Patient with a diagnosis of secondary myelofibrosis; - Pregnant or breastfeeding woman; - Person prived of liberty by judicial or administrative decision; - Person subject to a legal protection measure;

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Non-invasive diagnosis score
spleen fibrosis by elastography plasma cytokines levels mutationnal landscape by NGS CD34 circulating cells

Locations

Country Name City State
France Chu Angers Angers
France CHRU de Brest - Hôpital Morvan Brest

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary WHO 2016 criteria for prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis Assessment of the non-invasive diagnostic score against the WHO diagnosis At the time of diagnosis : disease classification
See also
  Status Clinical Trial Phase
Completed NCT04254978 - Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) Phase 2
Recruiting NCT05482971 - A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Recruiting NCT02897297 - Myeloproliferative Neoplastic Diseases Observatory From Brest
Completed NCT00666549 - Research Tissue Bank
Completed NCT00052520 - Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Phase 1/Phase 2
Completed NCT01192347 - French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Recruiting NCT04942080 - Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) N/A
Recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Active, not recruiting NCT04262141 - IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Phase 2
Completed NCT03907436 - The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase N/A
Active, not recruiting NCT00588991 - Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Phase 1
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT01787552 - A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF Phase 1/Phase 2
Recruiting NCT03116542 - 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia N/A
Recruiting NCT06361641 - Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes N/A
Recruiting NCT06378437 - A Study of GLB-001 in Patients With Myeloid Malignancies Phase 1
Recruiting NCT05882773 - Asian Myeloproliferative Neoplasm (MPN) Registry
Completed NCT02129101 - Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Phase 1